Nephro Trial Files Throwback Thursday: ARBs in Diabetic Nephropathy, Chlorthalidone in HTN, and EPO in CKD with Anemia
nephrotrialfiles.substack.com
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy (RENAAL) Brenner BM et al. NEJM (September 2001) Bottom Line: This randomized, double-blind study included 1513 patients with type 2 diabetes and nephropathy who were randomly assigned to receive either losartan (50 to 100 mg once daily) or placebo, both taken in addition to conventional antihypertensive treatment, for a mean of 3.4 years. The primary outcome was a composite of a doubling of the base-line serum creatinine concentration, end-stage renal disease, or death. Losartan reduced the incidence of a doubling of the serum creatinine concentration by 25 percent (P=0.006) and end-stage renal disease by 28 percent (P=0.002). Losartan also reduced the rate of first hospitalization for heart failure by 32 percent (P=0.005). The level of proteinuria declined by 35 percent with losartan (P<0.001 for the comparison with placebo). Losartan was generally well tolerated and conferred significant renal benefits.
Nephro Trial Files Throwback Thursday: ARBs in Diabetic Nephropathy, Chlorthalidone in HTN, and EPO in CKD with Anemia
Nephro Trial Files Throwback Thursday: ARBs…
Nephro Trial Files Throwback Thursday: ARBs in Diabetic Nephropathy, Chlorthalidone in HTN, and EPO in CKD with Anemia
Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy (RENAAL) Brenner BM et al. NEJM (September 2001) Bottom Line: This randomized, double-blind study included 1513 patients with type 2 diabetes and nephropathy who were randomly assigned to receive either losartan (50 to 100 mg once daily) or placebo, both taken in addition to conventional antihypertensive treatment, for a mean of 3.4 years. The primary outcome was a composite of a doubling of the base-line serum creatinine concentration, end-stage renal disease, or death. Losartan reduced the incidence of a doubling of the serum creatinine concentration by 25 percent (P=0.006) and end-stage renal disease by 28 percent (P=0.002). Losartan also reduced the rate of first hospitalization for heart failure by 32 percent (P=0.005). The level of proteinuria declined by 35 percent with losartan (P<0.001 for the comparison with placebo). Losartan was generally well tolerated and conferred significant renal benefits.